Animal drug shortages limit veterinary therapeutic options and introduce artifacts in antimicrobial sales reporting
-
Published:2024-01-03
Issue:
Volume:
Page:1-4
-
ISSN:0003-1488
-
Container-title:Journal of the American Veterinary Medical Association
-
language:
-
Short-container-title:javma
Author:
_ _, Robbins Rebecca C.1, Singer Randall S.2, Innes Gabriel K.3, Plummer Paul J.4, Apley Michael D.5, Gaunt Patricia S.6, Papich Mark G.7, Granick Jennifer8, Marshall Edith S.9, Smith David R.10, Frey Erin7, Cervantes Hector M.11, Beaudoin Amanda L.2, Canon Abbey J.12, Brookshire Cooper10, Buckley Michelle13, Whaley Janet14, Schnabel Lauren15, Costin Michael16
Affiliation:
1. Amarillo, TX 2. Saint Paul, MN 3. Baltimore, MD 4. Boone, IA 5. Manhattan, KS 6. Baton Rouge, LA 7. Raleigh, NC 8. Arden Hills, MN 9. Davis, CA 10. Mississippi State, MS 11. Watkinsville, GA 12. Rowan, IA 13. Ames, IA 14. Brookeville, MD 15. Holly Springs, NC 16. Schaumburg, IL
Abstract
Abstract
Supply chain issues disrupt veterinary care and cause downstream consequences that alter the practice of veterinary medicine. Antimicrobials are just 1 class of pharmaceuticals that have been impacted by supply chain issues over the last couple of years. Since February 2021, 2 sponsors/manufacturers of penicillin products have reported shortages in the active pharmaceutical ingredient. With the release of the 2021 Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals by the FDA, a key finding was a 19% decrease in penicillin sales and distribution from 2020 to 2021. Herein, we provide our clinicians’ professional perspective regarding how drug shortages, specifically that of penicillin, might contribute to misconstrued patterns in antimicrobial use and what can be done by veterinarians and the FDA to minimize the impact of an antimicrobial drug shortage on animal health and well-being.
Publisher
American Veterinary Medical Association (AVMA)
Reference13 articles.
1. Supply chain disruption during the COVID-19 pandemic: recognizing potential disruption management strategies;Moosavi J,2022 2. FDA 3. FDA 4. FDA 5. AVMA
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|